Moderna Slams Arbutus Bid to Dodge Vaccine-Patent Case Narrowing

May 20, 2025, 5:18 PM UTC

Moderna Inc. urged a Delaware federal judge to reject Arbutus Biopharma Corp.’s request to reconsider an order narrowing the number of patents Arbutus can assert in a lawsuit seeking royalties from Moderna’s Covid-19 shot, calling the move “unabashedly” inconsistent and “opportunistic.”

Moderna filed its opposition letter Monday in the US District Court for the District of Delaware, responding to a May 16 letter from Arbutus and its co-plaintiff, Genevant Sciences GmbH.

“Plaintiffs are unabashedly making different factual representations under the guise of ‘reconsideration’ so that their case is not similarly limited,” Moderna wrote, accusing Arbutus and Genevant of reversing course ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.